SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response

ABSTRACT: Abstract Background: Schizophrenia is a lifelong debilitating mental illness often characterized by hallucinations, delusions, and disorganized thought and behavior. Currently, antipsychotic medications serve as the best treatment option for schizophrenia, but clinical responses to antipsychotic medications are highly variable. Therefore, the demand for reliable biological predictors is high. A glutamate and N-methyl-d-asparate (NMDA) receptor hypofunction model based on pharmacologic and genetic studies have been suggested as an approach to study the pharmacogenetics of antipsychotic medications. Previous studies have shown clozapine (CLZ) displaces NMDAR antagonists and enhances NMDAR mediated neurotransmission. Previously, our group (Taylor et al, 2016) investigated 8 SNPs in the NMDAR

SUBMITTER: Chen C 

PROVIDER: S-EPMC5476033 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature